Explain the mechanism of acute respiratory distress syndrome

Reading File

Now I'll search the medical library and PubMed in parallel for ARDS mechanism content.

Finding Sources

Searching PubMed

"acute respiratory distress syndrome"[MeSH Terms] AND pathogenesis

Searching the Web

ARDS acute respiratory distress syndrome mechanism pathogenesis 2025

Good. Now I'll read the most relevant blocks in parallel — Murray & Nadel's main ARDS chapter and Goldman-Cecil, plus search for ARDS mechanism images.

Reading File

Searching Images

ARDS acute respiratory distress syndrome pathogenesis mechanism alveolar injury

Now let me get the dedicated ARDS mechanism chapter from Murray & Nadel and also find the ARDS block with the full pathogenesis content.

Finding Sources

Reading File

Let me find the main ARDS chapter in Murray & Nadel that covers pathogenesis in detail.

Finding Sources

Excellent — Robbins Pathology has a dedicated ARDS section and Fishman's has a detailed mechanism block. Let me read both in parallel.

Reading File

I have excellent content from Robbins Pathology. Let me now read the morphology and phases section in detail, and fetch the key ARDS mechanism diagram.

Reading File

Loading Image

I now have comprehensive content from Robbins Pathology, Murray & Nadel, and Fishman's, plus two excellent images. I have enough to compose a thorough answer.

Acute Respiratory Distress Syndrome (ARDS): Mechanism

ARDS is a syndrome of acute hypoxemic respiratory failure caused by diffuse alveolar injury. Its underlying basis is damage to both sides of the alveolar-capillary membrane — the endothelial lining of pulmonary capillaries and the epithelial lining of the alveolus — unleashing an amplifying inflammatory cascade.

The Central Mechanism Diagram

Healthy alveolus vs. acute lung injury in ARDS — showing neutrophil recruitment, ROS/protease release, surfactant inactivation, hyaline membrane formation, and edema

Fig. 11.2 from Robbins & Kumar Basic Pathology — healthy alveolus (left) vs. injured alveolus in ARDS (right)

Step-by-Step Pathogenesis

1. Initiating Insults

ARDS arises from direct (pulmonary) or indirect (systemic) insults to the lung:

Direct	Indirect
Pneumonia (35–45%)	Sepsis (30–35%)
Aspiration	Severe pancreatitis
Inhalational injury	Major trauma / multiple fractures
Pulmonary contusion	Transfusion reactions (TRALI)
COVID-19	Burns, hypotension

2. Innate Immune Activation

The initiating insult triggers alveolar macrophages to release proinflammatory cytokines — primarily IL-1, TNF-α, chemokines (IL-8, CXCL1), and platelet-activating factor. These mediators:

Activate pulmonary capillary endothelium (upregulating selectins and ICAM-1)
Attract and activate neutrophils, which sequester in pulmonary capillaries

"Release of factors such as IL-1 and TNF leads to endothelial activation and sequestration and activation of neutrophils in pulmonary capillaries." — Robbins & Kumar Basic Pathology

3. Neutrophil-Mediated Injury (The Central Effector)

Activated neutrophils are the primary mediators of tissue destruction. They degranulate and release:

Reactive oxygen species (ROS) — oxidative damage to endothelium and epithelium
Proteases (elastase, collagenase, matrix metalloproteinases) — degrade basement membrane and structural proteins
Leukotrienes and prostaglandins — amplify the inflammatory signal
Additional cytokines — self-perpetuating loop

The balance between these destructive forces and endogenous counterparts (antiproteases like α₁-antitrypsin; antioxidants like superoxide dismutase) determines clinical severity.

4. Breakdown of the Alveolar-Capillary Barrier

Neutrophil-mediated injury causes:

Endothelial damage → increased vascular permeability → protein-rich fluid floods the interstitium and alveolar spaces → non-cardiogenic pulmonary edema

Type I pneumocyte necrosis → loss of the thin gas-exchange epithelium → impaired alveolar fluid clearance

Type II pneumocyte injury → reduced surfactant synthesis and secretion; phospholipase A₂ (from pancreatitis) enzymatically degrades existing surfactant → surfactant dysfunction and inactivation

5. Surfactant Loss and Alveolar Collapse

Surfactant normally reduces surface tension in alveoli, preventing collapse at end-expiration. Its inactivation causes:

Diffuse alveolar collapse (atelectasis)
Decreased lung compliance (stiff lungs)
Intrapulmonary shunting → refractory hypoxemia

6. Coagulation Activation

Simultaneously, exposure of subendothelial collagen, release of tissue factor, and activation of platelets drives intravascular and intraalveolar fibrin deposition. This contributes to microvascular thrombosis (worsening perfusion) and formation of the pathognomonic hyaline membranes.

Histopathological Phases

The gross/microscopic picture of ARDS is diffuse alveolar damage (DAD), which evolves through three phases:

Phase 1: Exudative (Days 1–7)

Lungs are dark red, firm, airless, and heavy
Capillary congestion and interstitial edema
Hyaline membranes lining alveolar ducts — fibrin-rich exudate + necrotic epithelial debris (the most characteristic finding)
Neutrophilic infiltrates in capillaries and alveoli

Phase 2: Proliferative / Organizing (Days 7–21)

Type II pneumocyte proliferation attempting to re-epithelialize the denuded alveolar surface
Fibroblast infiltration, procollagen deposition
Hyaline membranes begin to be resorbed or organized

Phase 3: Fibrotic (Beyond 3 weeks)

Progressive alveolar septal fibrosis if repair fails
Permanent architectural remodeling
Reduced diffusion capacity and compliance

CT scan showing bilateral ground-glass opacities and H&E histology showing hyaline membranes (arrow) in DAD

Left: Chest CT with bilateral ground-glass opacities in ARDS. Right: H&E histology showing hyaline membranes (arrow) and alveolar wall thickening — hallmarks of diffuse alveolar damage.

Physiological Consequences

Mechanism	Physiological Effect
Alveolar flooding + atelectasis	↓ FRC; intrapulmonary shunt → refractory hypoxemia
Surfactant loss	↓ Lung compliance (stiff lungs)
Interstitial edema	Impaired O₂ diffusion
Microvascular thrombosis	↑ Dead space, pulmonary hypertension
Widespread inflammation	Systemic SIRS → risk of multiorgan failure

The hallmark clinical finding is a low PaO₂/FiO₂ ratio (Berlin definition: <300 mild, <200 moderate, <100 severe), reflecting the severity of ventilation-perfusion mismatch and shunt.

Key Cellular and Molecular Players Summary

Player	Role
Macrophages	IL-1, TNF-α, chemokine release — initiate cascade
Neutrophils	ROS, proteases, cytokines — execute alveolar damage
Type I pneumocytes	Primary target of injury; necrosis destroys gas-exchange surface
Type II pneumocytes	Surfactant production; proliferate in repair phase
Endothelium	Permeability barrier; injury causes edema
Coagulation system	Fibrin deposition; hyaline membrane formation; microvascular occlusion
Fibroblasts	Procollagen → fibrosis in late phase

Sources:

Robbins & Kumar Basic Pathology, Chapter 11 (Acute Lung Injury and ARDS)
Murray & Nadel's Textbook of Respiratory Medicine, Chapter 134
Fishman's Pulmonary Diseases and Disorders, Chapter on ARDS
Sabiston Textbook of Surgery, Chapter on Critical Care

This is a shared conversation. Sign in to Orris to start your own chat.